<bill session="117" type="h" number="4479" updated="2023-05-26T15:15:22Z">
  <state datetime="2021-07-16">REFERRED</state>
  <status>
    <introduced datetime="2021-07-16"/>
  </status>
  <introduced datetime="2021-07-16"/>
  <titles>
    <title type="official" as="introduced">To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, diagnostic radiopharmaceuticals under the Medicare hospital outpatient prospective payment system.</title>
    <title type="display">Facilitating Innovative Nuclear Diagnostics Act of 2021</title>
    <title type="short" as="introduced">Facilitating Innovative Nuclear Diagnostics Act of 2021</title>
  </titles>
  <sponsor bioguide_id="P000608"/>
  <cosponsors>
    <cosponsor bioguide_id="A000377" joined="2022-07-07"/>
    <cosponsor bioguide_id="A000148" joined="2022-03-30"/>
    <cosponsor bioguide_id="B001303" joined="2022-01-12"/>
    <cosponsor bioguide_id="B001275" joined="2022-05-24"/>
    <cosponsor bioguide_id="B001309" joined="2021-08-27"/>
    <cosponsor bioguide_id="C001112" joined="2022-05-06"/>
    <cosponsor bioguide_id="C001072" joined="2022-08-19"/>
    <cosponsor bioguide_id="C001103" joined="2022-07-01"/>
    <cosponsor bioguide_id="C001119" joined="2022-05-16"/>
    <cosponsor bioguide_id="C001097" joined="2021-10-28"/>
    <cosponsor bioguide_id="D000628" joined="2021-07-16"/>
    <cosponsor bioguide_id="F000465" joined="2022-06-08"/>
    <cosponsor bioguide_id="J000292" joined="2022-03-31"/>
    <cosponsor bioguide_id="J000302" joined="2022-07-11"/>
    <cosponsor bioguide_id="K000391" joined="2021-09-14"/>
    <cosponsor bioguide_id="K000382" joined="2021-11-17"/>
    <cosponsor bioguide_id="L000582" joined="2022-02-02"/>
    <cosponsor bioguide_id="L000579" joined="2022-04-07"/>
    <cosponsor bioguide_id="M001203" joined="2022-06-16"/>
    <cosponsor bioguide_id="M000312" joined="2021-10-08"/>
    <cosponsor bioguide_id="M001180" joined="2021-09-24"/>
    <cosponsor bioguide_id="M001215" joined="2022-11-15"/>
    <cosponsor bioguide_id="M001196" joined="2021-10-19"/>
    <cosponsor bioguide_id="M001190" joined="2021-09-17"/>
    <cosponsor bioguide_id="M001210" joined="2021-07-16"/>
    <cosponsor bioguide_id="P000614" joined="2022-10-28"/>
    <cosponsor bioguide_id="P000604" joined="2021-07-30"/>
    <cosponsor bioguide_id="P000616" joined="2022-07-07"/>
    <cosponsor bioguide_id="P000599" joined="2022-03-31"/>
    <cosponsor bioguide_id="R000610" joined="2021-08-06"/>
    <cosponsor bioguide_id="R000515" joined="2021-07-16"/>
    <cosponsor bioguide_id="R000609" joined="2022-03-02"/>
    <cosponsor bioguide_id="S001185" joined="2022-01-11"/>
    <cosponsor bioguide_id="S001172" joined="2022-01-13"/>
    <cosponsor bioguide_id="S000522" joined="2021-10-20"/>
    <cosponsor bioguide_id="S001200" joined="2022-02-02"/>
    <cosponsor bioguide_id="T000469" joined="2021-11-04"/>
    <cosponsor bioguide_id="T000482" joined="2022-02-07"/>
    <cosponsor bioguide_id="V000133" joined="2022-03-30"/>
    <cosponsor bioguide_id="W000813" joined="2022-03-15"/>
    <cosponsor bioguide_id="W000822" joined="2022-02-04"/>
  </cosponsors>
  <actions>
    <action datetime="2021-07-16">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-07-16" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-07-16">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-07-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2021-07-19">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSWM02" name="House Ways and Means" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="2609" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Health care costs and insurance"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Medicare"/>
    <term name="Radiation"/>
  </subjects>
  <amendments/>
  <summary date="2021-08-12T20:49:57Z" status="Introduced in House">Facilitating Innovative Nuclear Diagnostics Act of 2021

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2022 and as adjusted based on a specified fee schedule factor in each year thereafter.</summary>
</bill>
